Tacalyx Secures €11 Million for Cancer Therapy Development

Tacalyx GmbH, based in Berlin, has announced an €11 million funding boost to advance its TCX-201 programme. This breakthrough targets Tumour Associated Carbohydrate Antigens (TACAs) with the aim of addressing hard-to-treat cancers. The funds, sourced from an accomplished group of investors, will move TCX-201 through preclinical development and support an expanding pipeline of therapies.

TCX-201, a novel antibody drug conjugate (ADC), focuses on gastrointestinal and other solid tumours. TACAs, a challenging target historically, offer new hope in cancer therapeutics. Tacalyx's proprietary platform allows for high-affinity antibody discovery, enhancing treatment potential.

CEO Jean Engela expressed gratitude for investor support and highlighted the company’s mission to transform cancer therapies. A second clinical candidate is anticipated by late 2026, paving the way for further advancements in the field.